Ignite Creation Date:
2024-05-06 @ 12:33 AM
Last Modification Date:
2024-10-26 @ 10:51 AM
Study NCT ID:
NCT01605162
Status:
TERMINATED
Last Update Posted:
2016-07-28
First Post:
2012-05-22
Brief Title:
Phase 2 Study of the PolyADP-Ribose Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Unresectable Stage III Melanoma |
| Wild Type BRAF Stage IV Melanoma |
Keywords: